Dr. Obzut studies autoimmune diseases, especially autoimmune cytopenia, which occurs when the immune system attacks the body's own blood cells. In her research, she explores whether there are specific biological markers that can indicate underlying issues with the immune system in patients suffering from this condition. By identifying these markers, Dr. Obzut aims to help doctors diagnose immune disorders more accurately and enhance treatment options.
In addition, Dr. Obzut investigates rare tumors related to genetic mutations, particularly those that occur in the adrenal glands. Her research on a unique case involving a composite adrenal tumor sheds light on how genetic factors, like the TP53 mutation, correlate with an increased risk of cancer. This aspect of her work can significantly benefit patients with conditions like Li-Fraumeni syndrome.
Key findings
In her 2026 study, 51% of patients with autoimmune cytopenia were found to have inborn errors of immunity.
The highest rates of inborn errors of immunity were discovered in patients with autoimmune hemolytic anemia (62.5%) and Evans syndrome (61.5%).
Dr. Obzut's research on a composite adrenal tumor highlights the connection between specific genetic mutations and the likelihood of developing multiple cancers in patients with Li-Fraumeni syndrome.
Frequently asked questions
Does Dr. Obzut study autoimmune diseases?
Yes, Dr. Obzut focuses on autoimmune diseases, specifically examining autoimmune cytopenia and its underlying causes.
What conditions are relevant to Dr. Obzut's research?
Her research is relevant to patients with autoimmune diseases, particularly those with autoimmune cytopenia, as well as patients with rare tumors and genetic syndromes like Li-Fraumeni syndrome.
What biomarkers does Dr. Obzut investigate?
Dr. Obzut investigates biological markers that can help identify inborn errors of immunity in patients with autoimmune conditions, aiding in more accurate diagnosis and treatment.
How does Dr. Obzut's research help patients?
Her research helps patients by improving the understanding of their conditions, leading to better diagnosis and personalized treatment options.
Publications in plain English
Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.
2026
Pediatric blood & cancer
Gaál Z, Meehan C, Yilmaz M, Ujhazi B, Suhet P +49 more
Plain English This study looked at patients in the Tampa Bay area who have autoimmune cytopenia (AIC) to see if there are specific biological markers that indicate underlying immune disorders. Out of 104 patients, 53 (51%) were found to have inborn errors of immunity (IEI), with the highest rates (62.5% and 61.5%) in those with autoimmune hemolytic anemia and Evans syndrome. Identifying these markers is important because it can help doctors diagnose immune disorders more accurately and tailor treatments for patients.
Who this helps: This helps patients with autoimmune diseases and their doctors in diagnosing and managing their conditions.
Composite adrenal anaplastic neuroblastoma and virilizing adrenocortical tumor with germline TP53 R248W mutation.
2008
Pediatric blood & cancer
Rossbach HC, Baschinsky D, Wynn T, Obzut D, Sutcliffe M +1 more
Plain English This study looked at a rare type of tumor found in the adrenal glands that combines features of neuroblastoma and an adrenocortical tumor in a patient with a specific genetic mutation (TP53 R248W). The researchers noted that while this mutation is linked to a higher risk of various cancers through a condition called Li-Fraumeni syndrome, it is not yet clear if it also increases the risk for neuroblastoma. This research matters because understanding these rare tumors and their genetic links could help develop better treatment strategies for affected patients.
Who this helps: This helps patients with rare tumors and genetic syndromes, as well as their doctors.